Clinical Trial Update: Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery [Phase 2]

View source ↗

Summary

Phase 2 trial comparing cabozantinib-s-malate to temozolomide or dacarbazine in metastatic or unresectable uveal melanoma; completed with results posted in 2019…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Uveal Melanoma

Drugs mentioned

• Cabozantinib S-Malate (cabozantinib)
• Dacarbazine (dacarbazine)
• Temozolomide (Temozolomide)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Uveal Melanoma, Stage III Uveal Melanoma AJCC v7 | Phase 2 | Status: COMPLETED | Results posted: 2019-04-26